Course Description
This symposium will actively engage psychiatric and neurologic pharmacists by evaluating their knowledge in the screening of patients who present with depressive symptomatology for bipolar depression, as well as provide education on strategies for the increased recognition and improved treatment of the disorder. Of primary interest will be increasing pharmacists’ understanding of the data regarding the safety, efficacy, and tolerability of current and emerging therapies for bipolar depression and the application of this data to clinical practice. Both a didactic presentation and an interactive case study will highlight the key role pharmacists provide in the development of evidence-based treatment plans for patients with a diagnosis of bipolar depression; the assessment of treatment regimens based on adverse effects, breakthrough symptoms, and/or medical comorbidities; and patient education. An audience response system will be used to facilitate interactions between attendees and the expert faculty so as to optimize the learning experience.
Learning Objectives
- Identify screening tools for patients who present with depressive symptomatology for bipolar depression, discuss their validity and reliability, and how to use them to help differentiate patients from those with unipolar depression
- Evaluate the data regarding the safety, efficacy, and tolerability of current and emerging therapies for bipolar depression
- Develop evidence-based treatment plans for patients with a diagnosis of bipolar depression
- Assess treatment regimens based on adverse effects, breakthrough symptoms, and/or medical comorbidities
Target Audience
This course is designed for pharmacists, nurse practitioners or other healthcare professionals involved in the comprehensive medication management of psychiatric and/or neurological patients.
Faculty
View biographical information
Steven C. Stoner, PharmD, BCPP (Activity Chair)
Chair and Clinical Professor
Division of Pharmacy Practice and Administration
UMKC School of Pharmacy
Kansas City, Missouri
Terence Ketter, MD
Professor of Psychiatry and Behavioral Sciences, Stanford University School of Medicine
Chief, Bipolar Disorder Clinic, Stanford University Hospital and Clinics.
Stanford, California
Course Requirements
To receive ACPE credit for this session, you must:
- Register for this course.
- Review the full content of the activity and reflect upon its teachings.
- Complete the evaluation at the end of the activity.
- Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.
Continuing Education Credit and Disclosures
Activity Date: 04/20/2015
ACPE Contact Hours: 1.5
ACPE Number: 0284-9999-15-060-L01-P (Application)
Nursing Credit Reminder: Note that ACPE credit is accepted for ANCC Certification Renewal and AANPCB advanced practice provider content. For specific questions related to your organization's acceptance of ACPE continuing education units, please contact your organization directly.
The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This self-study course provides 1.5 contact hours (0.15 CEUs) of application-based continuing education credit from CPNP approved programming. The ACPE universal program number assigned to this course is 0284-9999-15-060-L01-P (1.5 contact hours).
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
View planning committee disclosures
Applicable meded Consulting and CPNP staff have nothing to disclose relating to the subject
matter of this activity.
All relevant relationships have been mitigated.
View disclaimer and disclosure of off-label use
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Presentation-Specific Disclosure: Presentation will include discussion of off-label, experimental, and/or investigational use of drugs or devices: Steven Stoner may discuss the use of antipsychotics, antidepressants, and mood stabilizers/antiepileptics that do not have a bipolar indication. Terence Ketter: armodafinil, antidepressants, anticonvulsants, mood stabilizers, and second generation antipsychotics for bipolar disorder
View fair balance and integrity statement
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.